Stem Cell Therapy for Cerebral Palsy: A Guide for Families Based on Published Science
Cerebral palsy (CP) is the most common motor disability in childhood, affecting approximately 17 million people worldwide. It results from non-progressive brain injury or abnormal brain development occurring before, during, or shortly after birth.
While the brain injury itself is stable, its functional consequences - motor impairment, spasticity, cognitive and communication challenges - evolve as the child grows.
For families, the search for therapies that support development and improve quality of life is constant. Stem cell therapy has become one of the most researched experimental options in this space, and the clinical evidence has matured considerably.
Why stem cells in Cerebral Palsy?
Unlike degenerative conditions where neurons are progressively lost, CP involves a fixed injury in a developing brain. The therapeutic rationale for stem cells in CP therefore draws on the unique biology of the developing nervous system:
Neuroplasticity is significantly higher in children's brains. Stem cell-mediated neuroprotective and neurotrophic signals can promote the reorganisation of neural circuits around the injury area in ways that are not possible in adult neurology.
Inflammation reduction is relevant even in CP - chronic neuroinflammation persists around the site of the original injury and limits functional recovery.
MSC secretome effects on spasticity, motor circuit modulation, and myelination are directly relevant to the functional deficits seen in CP.
What does the clinical evidence show?
The evidence base for stem cells in CP has reached a notable level of maturity:
- A comprehensive meta-analysis of controlled trials (Cryo-Cell, 2025) found that MSC therapy produced "small but statistically significant improvements in gross motor function" - the primary functional measure in CP.
- A study of repeated intrathecal injections of autologous bone marrow-derived MSCs in spastic CP demonstrated safe administration with significant improvements in motor function, balance, and spasticity.
- The American Academy of Pediatrics journal Pediatrics published an individual participant data meta-analysis of cord blood treatment for CP, confirming safety and gross motor benefit - with higher doses associated with greater effect size.
- Duke University's Marcus Center for Cellular Cures continues to run FDA-regulated clinical trials for CP using cord blood, representing institutional validation at the highest level.
Across studies, improvements have been documented in gross motor function, upper limb function, spasticity reduction, balance, and in some cases communication and cognition.
Timing - does it matter?
The evidence suggests earlier treatment in childhood is associated with better outcomes.
The window of highest neuroplasticity is roughly 1-10 years of age, though improvements have been documented in older children and adolescents.
For younger children with recent perinatal injury (hypoxic-ischemic encephalopathy, for example), the proximity to the injury event may also influence response - neuroprotective effects appear strongest closer in time to the initial injury.
Types of CP and Expected Outcomes
Spastic CP (most common, ~80%) - Best evidence base; MSC and cord blood therapies show motor and spasticity improvements.
Dyskinetic/athetoid CP - Some evidence of benefit, particularly for upper limb function and voluntary movement control.
Ataxic CP - Less studied, though balance and coordination improvements have been reported.
Hypotonic CP - Limited specific evidence, but neuroprotective and neurotrophic mechanisms are theoretically applicable.
Our Approach
We provide fully individualised advisory for families considering stem cell therapy for a child with cerebral palsy. Our process includes review of the child's current functional assessments (GMFCS level, physiotherapy reports, MRI findings where available), identification of the most appropriate published protocol, and clinical partner matching.
We understand that this is an intensely personal decision. Our role is to ensure you have complete, honest, science-based information - and that if you proceed, it is with a GMP-certified, regulated protocol that has been peer-reviewed.
Frequently Asked Questions
My child is 12 - is it too late for stem cell therapy for CP?
The evidence is strongest for younger children, but improvements have been documented in adolescents. The key is whether functional neuroplasticity is still present, which can be assessed neurologically. We will give you an honest assessment based on your child's specific profile.
What is the difference between cord blood treatment and MSC treatment?
Cord blood contains a mixture of haematopoietic and other stem cell types including endothelial progenitors. Mesenchymal stem cells derived from bone marrow or umbilical cord tissue
are more targeted immunomodulatory agents. Cord blood is often used in younger children (especially those with access to banked cord blood), while allogeneic MSC protocols are available regardless of whether cord blood was stored. Both have published evidence in CP; we assess which is more appropriate for your child.
Will my child need physiotherapy alongside the treatment?
Yes - all published protocols combine stem cell therapy with active rehabilitation. The therapy creates a neurobiological window of enhanced plasticity; physiotherapy and occupational therapy are essential to translate that into functional gains.